Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110186 | 0.90 | ESR1 (0.57) | ESR1ESR2HDAC2MIFMAPT | |
| SCHEMBL5110464 | 0.90 | ESR1 (0.57) | ESR1ESR2HDAC2MIFMAPT | |
| SCHEMBL14289690 | 0.85 | ESR1 (0.48) | ESR1ESR2HDAC2AKT1AKT2 | |
| SCHEMBL5109423 | 0.85 | ESR1 (0.66) | ESR1ESR2MIFBACE1 | |
| SCHEMBL5109426 | 0.85 | ESR1 (0.66) | ESR1ESR2MIFBACE1 | |
| SCHEMBL5116818 | 0.83 | ESR1 (0.60) | ESR1ESR2HDAC2MAPTBACE1 | |
| SCHEMBL5124386 | 0.83 | ESR1 (0.60) | ESR1ESR2HDAC2MAPTBACE1 | |
| SCHEMBL6441021 | 0.82 | HDAC1 (0.45) | ESR1ESR2HDAC2 | |
| SCHEMBL5114409 | 0.82 | HDAC1 (0.45) | ESR1ESR2HDAC2 | |
| SCHEMBL6437655 | 0.82 | ESR1 (0.43) | ESR1ESR2HDAC2MIFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | claimed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | claimed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1417169-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | ESR1 1/4885ESR2 8/4885HDAC2 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.